Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase‐3, randomized, placebo‐controlled trial

BACKGROUND: Few clinical trials have evaluated long‐term treatment of nail psoriasis with biologics. OBJECTIVE: Safety and efficacy of adalimumab [ADA; Humira AbbVie Inc, North Chicago, IL, USA)] long‐term treatment (52 weeks) was evaluated in a phase‐3, randomized trial in patients with moderate‐to...

Descripción completa

Detalles Bibliográficos
Autores principales: Elewski, B.E., Baker, C.S., Crowley, J.J., Poulin, Y., Okun, M.M., Calimlim, B., Geng, Z., Reyes Servin, O., Rich, P.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Nails
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899987/
https://www.ncbi.nlm.nih.gov/pubmed/31304993
http://dx.doi.org/10.1111/jdv.15793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899987/
https://www.ncbi.nlm.nih.gov/pubmed/31304993
http://dx.doi.org/10.1111/jdv.15793

Ejemplares similares